Main content area

Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells

Li, Peng, Zhong, Di, Gong, Pei-yao
Biochemical and biophysical research communications 2019 v.516 no.1 pp. 183-188
Western blotting, breast neoplasms, cell cycle, cell proliferation, doxorubicin, flow cytometry, inhibitory concentration 50, multiple drug resistance, neoplasm cells, paclitaxel, synergism, therapeutics, verapamil
The aim of this study was to investigate the synergistic effect of paclitaxel (PTX) and verapamil (VERA) on adriamycin (ADR)-resistant breast cancer (MCF-7/ADR) cells.ATP-PCA was applied to determine the inhibitory effects of PTX combined with VERA on MCF-7/ADR cells. Edu, CCK-8 and Flow cytometry (FCM), Annexin V-FITC binding and Western blot were used to analyze the effects of combination therapy with PTX and VERA on cell proliferation, progression of cell cycle and cell apoptosis.PTX-based treatments with VERA enhanced killing effect on MCF-7/ADR cells. IC50 value of cell was significantly decreased in combination treatment compared with PTX administrated. VERA enhanced the efficacy and sensitivity of PTX to MCF-7/ADR cells. Combination of PTX and VERA could inhibit cell proliferation via arresting progression of cell cycle and promote cell apoptosis.PTX, along with VERA, had a synergistic action in anti-tumor response and may be proposed as a novel treatment strategy for chemo-resistant breast cancer.